Sample Letter of Formulary Exception

Accurate completion of reimbursement-related or coverage-related documentation is the responsibility of the provider and patient. Pfizer makes no guarantee regarding reimbursement for any service or item.

The information contained in this template letter is provided by Pfizer for informational purposes for patients who have been prescribed BRAFTOVI® in combination with MEKTOVI®. There is no requirement that any patient or healthcare provider use BRAFTOVI® in combination with MEKTOVI® in exchange for this information, and this template letter is not meant to substitute for a prescriber's independent medical decision-making.

[Insert Physician Letterhead]

Attn: [Insert Name of Pharmacy Director]
[Insert Insurer/Health Plan Name]
[Insert Address]
[Insert City, State, ZIP]

RE: [Insert Patient Full Name]
[Insert Gender and Date of Birth]
[Insert Policy Number]
[Insert Group Number]
[Insert Claim Number]

REQUEST: Authorization for treatment with BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib)
DIAGNOSIS: [placeholder for diagnosis] [Insert ICD-10-CM]
DOSAGE: [Insert dose, frequency, and days supplied]
REQUEST TYPE: ☐ Standard ☐ Expedited
APPEAL LEVEL: ☐ First Level (Ref. #:) ☐ Second Level (Ref. #:) ☐ Third Level (Ref. #:)

[Insert Date]

Dear [Insert name]:
I am writing on behalf of my patient, [insert patient name], to request a formulary exception for BRAFTOVI® in combination with MEKTOVI®.

My request is supported by the following:

Summary of Patient's Diagnosis
[Insert patient's diagnosis, date of diagnosis, lab results and date, and current medical condition]

Summary of Treatment History [Exercise medical judgement and discretion when inserting the following:
- Diagnosis (ICD-10-CM) and dates of initial diagnosis and recurrence (if applicable)
- Confirmed biomarker status via FDA-approved test
- Laboratory/imaging results and pathology reports
- If applicable, prior treatments and procedures for the cancer (dosage, duration, clinical response, and reasons for discontinuation)
- Current condition, comorbidities, and intolerance to other therapies
- Physician opinion of patient prognosis or disease progression]

Rationale for Treatment
Considering the patient's medical history, current medical condition, and the supporting use of BRAFTOVI® in combination with MEKTOVI®, I believe treatment with BRAFTOVI® in combination with MEKTOVI® at this time is warranted, appropriate, and medically necessary for this patient. For BRAFTOVI® in combination with MEKTOVI® clinical information, please see the accompanying full Prescribing Information documents [and additional supporting documentation].

Please contact me at [insert phone number or e-mail address] if you require any additional information or documentation. I look forward to your timely response.

Sincerely,
[Insert physician name and participating provider number]

If this request is denied, I am requesting an expedited review of appeal by a professional in my specialty.

Enclosure:
- BRAFTOVI® full Prescribing Information and MEKTOVI® full Prescribing Information
- [Insert any additional supporting documentation (e.g., published articles and clinical guidelines from ASCO or NCCN, laboratory/imaging results and pathology reports, and medical records documenting treatment history)]